Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.

Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Ji L, Zhan S

Endocrine13 Aug 2014Cited by 33 (Europe PMC)

PMID25115635DOI10.1007/s12020-014-0373-0PepBankPUB-25115635

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.8 mg once daily reduced waist circumference versus placebo by 5.24 cm in the network meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg daily reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference, liraglutide 1.8 mg once daily versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once dailyAs given in this study (human).
Measurements
Waist circumference, weighted mean difference
−5.24 cm
liraglutide 1.8 mg vs placebo
Source sentences
Summary
Overall, significant reductions on waist circumference following treatment of liraglutide--1.8 mg once daily (-5.24 cm, 95% CI -7.68, -2.93), liraglutide--1.2 mg once daily (-4.73 cm, 95% CI -6.68, -2.65) and exenatide--10 μg twice daily (-1.34 cm, 95 % CI -2.00, -0.75) were detected versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563501
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 mg once daily reduced waist circumference versus placebo by 4.73 cm in the network meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg daily reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference, liraglutide 1.2 mg once daily versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg once dailyAs given in this study (human).
Measurements
Waist circumference, weighted mean difference
−4.73 cm
liraglutide 1.2 mg vs placebo
Source sentences
Summary
Overall, significant reductions on waist circumference following treatment of liraglutide--1.8 mg once daily (-5.24 cm, 95% CI -7.68, -2.93), liraglutide--1.2 mg once daily (-4.73 cm, 95% CI -6.68, -2.65) and exenatide--10 μg twice daily (-1.34 cm, 95 % CI -2.00, -0.75) were detected versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563502
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.8 mg once daily reduced waist circumference more than sitagliptin by 1.73 cm.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg daily reduced waist size more than sitagliptin.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference, liraglutide 1.8 mg versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once dailyAs given in this study (human).
Measurements
Waist circumference, weighted mean difference
−1.73 cm
liraglutide 1.8 mg vs sitagliptin
Source sentences
Summary
Besides, liraglutide--1.8 mg once daily significantly decreased waist circumference by -1.73 cm (95 % CI -3.04, -0.55) versus sitagliptin
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563505
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 mg once daily did not differ significantly from liraglutide 1.8 mg once daily for waist circumference.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg and 1.8 mg daily changed waist size by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeWaist circumference, liraglutide 1.2 mg versus liraglutide 1.8 mg
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg once dailyAs given in this study (human).
Source sentences
Summary
whereas no significant difference following liraglutide--1.2-mg-once-daily treatment was detected compared with liraglutide--1.8 mg once daily and sitagliptin.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563506
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 mg once daily did not differ significantly from sitagliptin for waist circumference.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg daily and sitagliptin changed waist size by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeWaist circumference, liraglutide 1.2 mg versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg once dailyAs given in this study (human).
Source sentences
Summary
whereas no significant difference following liraglutide--1.2-mg-once-daily treatment was detected compared with liraglutide--1.8 mg once daily and sitagliptin.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563507
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.8 mg once daily had a 98.36% ranking probability of reducing waist circumference most among 12 treatments.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg daily ranked as most likely to reduce waist size among 12 treatments.
Peptide
Liraglutide
Outcome
DecreaseRanking probability for waist circumference reduction, liraglutide 1.8 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once dailyAs given in this study (human).
Measurements
Ranking probability
98.36%
liraglutide 1.8 mg
Source sentences
Summary
Ranking probability analysis indicated liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily decreased waist circumference most among all 12 treatments with probability of 98.36% and 91.82%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563508
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 mg once daily had a 91.82% ranking probability of reducing waist circumference most among 12 treatments.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg daily ranked among the most likely to reduce waist size among 12 treatments.
Peptide
Liraglutide
Outcome
DecreaseRanking probability for waist circumference reduction, liraglutide 1.2 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg once dailyAs given in this study (human).
Measurements
Ranking probability
91.82%
liraglutide 1.2 mg
Source sentences
Summary
Ranking probability analysis indicated liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily decreased waist circumference most among all 12 treatments with probability of 98.36% and 91.82%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
Report a problemFND-2511563509

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists reduced waist circumference more evidently when compared with insulin and thiazolidinediones (range -1.71 to -8.03 cm).
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group reduced waist size more than insulin and thiazolidinediones.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference, GLP-1 receptor agonists versus insulin and thiazolidinediones
Study
n: not reported in source
Comparator
Insulin and thiazolidinediones
Outcome group
Body weight · Metabolic and weight
Measurements
Waist circumference difference
−8.03 to −1.71 cm
GLP-1RAs vs insulin and thiazolidinediones
Source sentences
Summary
The reduction effect was more evident when compared with insulin and thiazolidinediones (range -1.71 to -8.03 cm).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2511563503
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 0.6, 1.2 and 1.8 mg and taspoglutide together decreased waist circumference versus exenatide, from -3.32 to -6.01 cm.
In plain wordsIn adults with type 2 diabetes, liraglutide and taspoglutide as a group reduced waist size more than exenatide.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference, liraglutide doses and taspoglutide versus exenatide
Study
n: not reported in source
Comparator
Exenatide
Outcome group
Body weight · Metabolic and weight
Measurements
Waist circumference difference
−6.01 to −3.32 cm
grouped agents vs exenatide
Source sentences
Summary
Compared with exenatide, liraglutide--0.6 mg once daily, taspoglutide, liraglutide--1.2 mg once daily and liraglutide--1.8 mg once daily significantly decreased waist circumference from -3.32 to -6.01 cm.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks.
Summary · context
Seventeen trials with 12 treatments were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2511563504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.